Clinical trial
Anti-Tac for Treatment of Leukemia
NCT00001941 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001941 |
|---|---|
| Title | Anti-Tac for Treatment of Leukemia |
| Official title | A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HTLV-I Infection, T Cell Leukemia |
| Intervention type | Biological |
| Interventions | daclizumab |
| Enrollment | 34 |
| Start date | Dec 1, 1999 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Jan 19, 2000 |
| Last update posted | Aug 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: